FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893724941> ?p ?o ?g. }

• W2893724941 abstract "Abstract Reticulocyte invasion by Plasmodium vivax requires interaction of the Duffy-binding protein (PvDBP) with host Duffy antigen receptor for chemokines (DARCs). The binding domain of PvDBP maps to a cysteine-rich region referred to as region II (PvDBPII). Blocking this interaction offers a potential path to prevent P. vivax blood-stage growth and P. vivax malaria. This forms the rationale for development of a vaccine based on PvDBPII. Here we report results of a Phase I randomized trial to evaluate the safety and immunogenicity of recombinant PvDBPII formulated with glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE). Thirty-six malaria-naive, healthy Indian male subjects aged 18–45 years were assigned into three cohorts corresponding to doses of 10, 25 and 50 µg of PvDBPII formulated with 5 µg of GLA-SE. Each cohort included nine PvDBPII/GLA-SE vaccinees and three hepatitis B control vaccine recipients. Each subject received the assigned vaccine intramuscularly on days 0, 28 and 56, and was followed up till day 180. No serious AE was reported and PvDBPII/GLA-SE was well-tolerated and safe. Analysis by ELISA showed that all three doses of PvDBPII elicited antigen-specific binding-inhibitory antibodies. The 50 µg dose elicited antibodies against PvDBPII that had the highest binding-inhibitory titres and were most persistent. Importantly, the antibody responses were strain transcending and blocked receptor binding of diverse PvDBP alleles. These results support further clinical development of PvDBPII/GLA-SE to evaluate efficacy against sporozoite or blood-stage challenge in controlled human malaria infection (CHMI) models and against natural P. vivax challenge in malaria endemic areas." @default.
• W2893724941 created "2018-10-05" @default.
• W2893724941 creator A5008275018 @default.
• W2893724941 creator A5011187406 @default.
• W2893724941 creator A5012176488 @default.
• W2893724941 creator A5013603248 @default.
• W2893724941 creator A5015850553 @default.
• W2893724941 creator A5016047736 @default.
• W2893724941 creator A5021986597 @default.
• W2893724941 creator A5023295794 @default.
• W2893724941 creator A5023917983 @default.
• W2893724941 creator A5024670697 @default.
• W2893724941 creator A5025203941 @default.
• W2893724941 creator A5026124300 @default.
• W2893724941 creator A5037630000 @default.
• W2893724941 creator A5045761029 @default.
• W2893724941 creator A5046032923 @default.
• W2893724941 creator A5047692833 @default.
• W2893724941 creator A5048238160 @default.
• W2893724941 creator A5048755670 @default.
• W2893724941 creator A5053862975 @default.
• W2893724941 creator A5055421590 @default.
• W2893724941 creator A5057697338 @default.
• W2893724941 creator A5058911046 @default.
• W2893724941 creator A5062986553 @default.
• W2893724941 creator A5072667047 @default.
• W2893724941 creator A5073687003 @default.
• W2893724941 creator A5081560485 @default.
• W2893724941 creator A5083230543 @default.
• W2893724941 creator A5088398681 @default.
• W2893724941 creator A5089454232 @default.
• W2893724941 creator A5089725912 @default.
• W2893724941 date "2018-09-28" @default.
• W2893724941 modified "2023-10-12" @default.
• W2893724941 title "Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial" @default.
• W2893724941 cites W1515527087 @default.
• W2893724941 cites W1917402522 @default.
• W2893724941 cites W1936185938 @default.
• W2893724941 cites W1969341911 @default.
• W2893724941 cites W1979111507 @default.
• W2893724941 cites W1979611404 @default.
• W2893724941 cites W1992816019 @default.
• W2893724941 cites W1994875191 @default.
• W2893724941 cites W1996453015 @default.
• W2893724941 cites W2078554713 @default.
• W2893724941 cites W2112395530 @default.
• W2893724941 cites W2118210994 @default.
• W2893724941 cites W2119040598 @default.
• W2893724941 cites W2132078046 @default.
• W2893724941 cites W2134054893 @default.
• W2893724941 cites W2137862593 @default.
• W2893724941 cites W2139282977 @default.
• W2893724941 cites W2151383900 @default.
• W2893724941 cites W2208817220 @default.
• W2893724941 cites W2462041221 @default.
• W2893724941 cites W2560702662 @default.
• W2893724941 cites W2626760342 @default.
• W2893724941 cites W2752966429 @default.
• W2893724941 cites W2791746431 @default.
• W2893724941 doi "https://doi.org/10.1038/s41541-018-0083-3" @default.
• W2893724941 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6162314" @default.
• W2893724941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30302285" @default.
• W2893724941 hasPublicationYear "2018" @default.
• W2893724941 type Work @default.
• W2893724941 sameAs 2893724941 @default.
• W2893724941 citedByCount "46" @default.
• W2893724941 countsByYear W28937249412019 @default.
• W2893724941 countsByYear W28937249412020 @default.
• W2893724941 countsByYear W28937249412021 @default.
• W2893724941 countsByYear W28937249412022 @default.
• W2893724941 countsByYear W28937249412023 @default.
• W2893724941 crossrefType "journal-article" @default.
• W2893724941 hasAuthorship W2893724941A5008275018 @default.
• W2893724941 hasAuthorship W2893724941A5011187406 @default.
• W2893724941 hasAuthorship W2893724941A5012176488 @default.
• W2893724941 hasAuthorship W2893724941A5013603248 @default.
• W2893724941 hasAuthorship W2893724941A5015850553 @default.
• W2893724941 hasAuthorship W2893724941A5016047736 @default.
• W2893724941 hasAuthorship W2893724941A5021986597 @default.
• W2893724941 hasAuthorship W2893724941A5023295794 @default.
• W2893724941 hasAuthorship W2893724941A5023917983 @default.
• W2893724941 hasAuthorship W2893724941A5024670697 @default.
• W2893724941 hasAuthorship W2893724941A5025203941 @default.
• W2893724941 hasAuthorship W2893724941A5026124300 @default.
• W2893724941 hasAuthorship W2893724941A5037630000 @default.
• W2893724941 hasAuthorship W2893724941A5045761029 @default.
• W2893724941 hasAuthorship W2893724941A5046032923 @default.
• W2893724941 hasAuthorship W2893724941A5047692833 @default.
• W2893724941 hasAuthorship W2893724941A5048238160 @default.
• W2893724941 hasAuthorship W2893724941A5048755670 @default.
• W2893724941 hasAuthorship W2893724941A5053862975 @default.
• W2893724941 hasAuthorship W2893724941A5055421590 @default.
• W2893724941 hasAuthorship W2893724941A5057697338 @default.
• W2893724941 hasAuthorship W2893724941A5058911046 @default.
• W2893724941 hasAuthorship W2893724941A5062986553 @default.
• W2893724941 hasAuthorship W2893724941A5072667047 @default.
• W2893724941 hasAuthorship W2893724941A5073687003 @default.
• W2893724941 hasAuthorship W2893724941A5081560485 @default.
• W2893724941 hasAuthorship W2893724941A5083230543 @default.
• W2893724941 hasAuthorship W2893724941A5088398681 @default.

• next